Navigation Links
Axial Biotech Names New VP of Reimbursement and Regulatory Affairs
Date:8/29/2008

Experienced Executive Rina Wolf Well-Positioned to Help Drive Company

Growth

SALT LAKE CITY, Aug. 29 /PRNewswire/ -- Axial Biotech, Inc., a company poised to revolutionize spine care through the development of molecular diagnostic and motion preserving technologies, announced today that it has named Rina Wolf as the company's new Vice President of Reimbursement and Regulatory Affairs.

In her new role, Wolf will be responsible for the creation and implementation of reimbursement strategies and policies. As Axial's liaison to the laboratory community, she will continue her active role in matters relating to reimbursement and regulatory initiatives that impact molecular diagnostics.

John Climaco, President and CEO of Axial Biotech, stated, "One of the key components of Axial's future success will be achieving appropriate levels of insurance coverage for our products and Ms. Wolf's vast experience in this area is second to none. In addition, she brings to our company an unparalleled level of understanding of the complex and rapidly evolving regulatory landscape around molecular diagnostics."

In her most recent role as VP of Reimbursement and Regulatory Affairs with RedPath Integrated Pathology, Wolf was responsible for creating and managing all billing polices and activities, patient advocacy programs, and public/private payer coverage and contracting. This included gaining a favorable Coverage Article for PathFinderTG(R) with RedPath's MAC.

Prior to joining RedPath, Wolf was the Director of Reimbursement and Payer Relations for Genomic Health, Inc. where she helped to develop reimbursement strategies and programs that led to positive coverage policies with major third party payers, as well as a favorable local coverage determination from Genomic Health's Part B Medicare Carrier.

Wolf has also worked at Esoterix (now LabCorp) as Vice President of Contracts, and has worked at both Scheri
'/>"/>

SOURCE Axial Biotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
4. BioSpace and BayBio announce 2008-2009 Biotech Bay(TM) Hotbed Campaign
5. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
6. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
7. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
9. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
10. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... basic Naltrexone HCL information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:10/30/2014)... San Diego, CA (PRWEB) October 30, 2014 ... company announced today that they have manually curated public ... Pharma and non profit customers. the data is ... BioSciences manually curates and unifies public and internal data ... more value and knowledge out of the data that ...
(Date:10/30/2014)... New York, NY (PRWEB) October 30, 2014 ... investment plan for its ICH Stability Testing and Package ... companies, this investment centers on a dramatic increase in ... larger volume of stability, storage and aging samples to ... first stage of this major capital expenditure has already ...
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... 8:30 a.m. ET in Boston, MA. ... available on the "Investors & Media" section of the Company,s ... the Isis website within 48 hours and will be archived ...
Breaking Biology Technology:Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... Inc. (NYSE: CRY ), an implantable biological medical ... it has filed an IDE with the United States ... the purpose of obtaining Pre-Market Approval (PMA) to distribute PerClot ... following traumatic injuries. PerClot is a unique, ...
... EMERYVILLE, Calif., April 4, 2011 Newly proposed ... patient care under healthcare reform closely mirror quality ... the American healthcare system, a MedeAnalytics analysis has ... The quality measure analysis is included ...
... April 4, 2011 Techne Corporation (NASDAQ: ... April 1, 2011, its R&D Systems subsidiary has ... leading developer and manufacturer of innovative ubiquitin-related research ... that facilitate and accelerate basic research and drug ...
Cached Biology Technology:CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 2CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 3CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 4ACO Proposed Rule: Nine out of Ten Quality Measures Mirror Other Quality Reporting Programs 2Techne Corporation Announces Acquisition 2Techne Corporation Announces Acquisition 3Techne Corporation Announces Acquisition 4
(Date:10/28/2014)... Health (NIH) announced awards to expand the Office ... Center for Advancing Translational Sciences (ORDR-NCATS) collaborative Rare ... network, physician scientists at 22 consortia will work ... research and investigate new treatments for patients with ... $29 million in fiscal 2014 funding from NIH. ...
(Date:10/28/2014)... in a novel environment are linked to individual ... experimental study completed at the University of Eastern ... Institute. The study used novel, long-term observations of ... to analyse if behaviours predict the vulnerability to ... enriched hatchery rearing environments. Based on the ...
(Date:10/28/2014)... associated with a lower risk of developing ovarian cancer, ... Anglia (UEA). , Research published today reveals that ... subclasses of dietary flavonoids) significantly decrease their risk of ... death among women. , The research team studied ... and 55 for more than three decades. , ...
Breaking Biology News(10 mins):NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3Fish 'personality' linked to vulnerability to angling 2Tea and citrus products could lower ovarian cancer risk, new UEA research finds 2
... for a University of Alberta paleontology researcher, who after months of ... as a new species of pterosaur, a flying reptile that lived ... stumped when the small piece of jaw bone was first pulled ... A,s paleontology department. "It could have been from a dinosaur, ...
... 4, 2011) − Scientists at the University of Kentucky have ... break up blood clots, speeds up the progress of prion ... plasminogen a promising new target for the development of drugs ... senior author Chongsuk Ryou, a researcher at the UK Sanders-Brown ...
... Lithuania, Jan. 10, 2011 Neurotechnology , ... announced the release of MegaMatcher 4.0 , ... fingerprint, iris, facial and palmprint biometrics in a ... MegaMatcher 4.0, Neurotechnology has incorporated palmprint technology along ...
Cached Biology News:Research identifies drug target for prion diseases, 'mad cow' 2New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK 2New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK 3
... deuterium atoms at the 3, 3', 4, ... use as an internal standard for the ... spectrometry. PGE1 is the theoretical cyclooxygenase metabolite ... virtually undetectable in the plasma of normal ...
Assay Diluent Trial Pack, 4 x 100 mL...
... Turn routine agarose gel electrophoresis into ... 96 system. This bufferless, pre-cast system is ... preparations, restriction digests, and more. Fully automated, ... the E-Gel 96 system makes your high-throughput ...
... The CopyControl™ PCR Cloning Kits are designed ... to ensure that all PCR products, regardless of ... cloned. All PCR products including those that are ... or that may be unstable or code for ...
Biology Products: